Should AR-V7 Be Used As A Clnical Test? - Philip Kantoff

Phillip Kantoff, MD provides his perspective on the role of AR-V7 as a clincial test.  (Presentation in 10 minutes).


Philip Kantoff, MD., is the Chair, Department of Medicine; The George J. Bosl Chair Memorial Sloan Kettering Cancer Center.  He is a board-certified medical oncologist and researcher specializing in the treatment of genitourinary cancers. His lab focuses on understanding the genetics and genetic epidemiology of prostate cancer, and the discovery of novel treatments for genitourinary cancers. As Chair of the Department of Medicine at Memorial Sloan Kettering, he oversee a department that is leading the development and testing of better cancer therapies.

Before coming to MSK, he served as Director of the Lank Center for Genitourinary Oncology, Chief of the Division of Solid Tumor Oncology, Vice Chair of the Department of Medical Oncology, and Chair of the Executive Committee on Clinical Research at the Dana-Farber Cancer Institute. He is a professor of medicine at Harvard Medical School, the Chairman of the Global Treatment Science Network of the Prostate Cancer Foundation, and a member of numerous professional societies and editorial boards.

Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Access to all Advanced Prostate Cancer Consensus Conference Video Coverage